Molecule intelOpportunity: ModerateEssential

Dapagliflozin

48 brands · 14 companies · product forms

ATC: A10BK01

Opportunity snapshot

Launch attractiveness
47
Market saturation
42
Price room
100
Regulatory risk
0
48
brands
14
companies
Rs 399
median price
61
price points
31.43x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 10%

Price room

Across observed sources and strengths
CheapestRs 101.64
MedianRs 399
Most expensiveRs 3,194.46
Spread31.43×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 31.43x across 61 trusted points (Rs 101.64-3194.46). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Dapagliflozin — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(58) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

14 canonical companies and 48 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 31.43x across 61 trusted points (Rs 101.64-3194.46). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.